Updated on 26 October 2026
Synthetic patient data and in silico test environments for biomedical research
CEO & Co-founder at K01
Reykjavík, Iceland
About
OFFERING
K01 develops synthetic health data as a computational methodology for biomedical research and regulatory testing:
-
Clinically realistic synthetic patient cohorts preserving statistical properties and physiological relationships
-
In silico test environments for algorithm development and validation
-
Differential privacy with configurable, mathematically verifiable privacy guarantees
-
FHIR R4/R5 compliant output for integration with research infrastructure
-
Roadmap includes medical imaging, genomics, and biosignals
Our approach enables computational experimentation without real patient data access, directly supporting NAM adoption in health research.
TRACTION
-
Live deployments with Icelandic health institutions
-
Icelandic government grant for healthcare simulation applications
-
Founded by two Imperial College London PhDs
LOOKING FOR
-
Coordinator with regulatory science or computational biology expertise
-
Partners developing models requiring synthetic training/validation data
-
Research institutions exploring alternatives to traditional data access
Open to RIA consortium roles in data infrastructure, privacy-preserving methods or in silico validation work packages.
Similar opportunities
Project cooperation
Synthetic health data infrastructure data low-value care detection
Arinbjörn Kolbeinsson
CEO & Co-founder at K01
Reykjavík, Iceland
Project cooperation
Partner for clinical AI evaluation, privacy-preserving data use and in-silico patient models
- Partner seeks Consortium/Coordinator
- Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
- Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Arinbjörn Kolbeinsson
CEO & Co-founder at K01
Reykjavík, Iceland
Project cooperation
R&D for Rare Disease Precision Medicine
- Destination 5: HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare
- Destination 1: HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Quy VO-REINHARD
CEO at Genorare
Zurich, Switzerland